# Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06736717/  
OnCo record `nct06736717` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of onvansertib and nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) in pancreatic cancer, run by University of Kansas Medical Center, now recruiting.

## Summary

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06736717 by University of Kansas Medical Center, with a registry enrolment figure of 21 participants, started 2025-02 and due to reach its primary completion in 2026-07. Interventions recorded: Onvansertib; NALIRIFOX. Conditions listed: Pancreatic Cancer. Primary outcome: Overall Response Rate (ORR). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PANCONVA
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06736717
- Phase: 1/2
- Setting: A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
- Sponsor: University of Kansas Medical Center
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT06736717: https://clinicaltrials.gov/study/NCT06736717

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)](https://onco.cc/drugs/nalirifox/), [Onvansertib](https://onco.cc/drugs/onvansertib/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06736717.json